clustered regularly interspaced short palindromic repeats crispr gene editing targeting hbg1 and hbg2 promoters to modify hematopoietic stem and progenitor cells hspc for the treatment of transfusion dependent beta thalassemia tdt clinical trial intelligence

A Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited Cluster of Differentiation 34 (CD34+) Human Hematopoietic Stem and Progenitor Cells (HSPC) (EDIT-301) in Transfusion-Dependent Beta Thalassemia (TDT)

EDIT-301, developed by Editas Medicine, Inc., represents a novel gene therapy approach for treating Transfusion-Dependent Beta Thalassemia, a condition affecting approximately 60,000 individuals in the U.S. and Europe. The asset is positioned within a competitive landscape that includes other gene therapies and hematopoietic stem cell transplantation options. Successful outcomes could lead to significant market penetration, particularly if EDIT-301 demonstrates sustained transfusion independence and reduced iron overload, addressing unmet medical needs. The trial's multicenter design enhances recruitment potential and data robustness, while the active status indicates ongoing engagement with regulatory bodies, which may facilitate expedited pathways for approval.

Matched by target_normalized: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) gene editing targeting HBG1 and HBG2 promoters to modify hematopoietic stem and progenitor cells (HSPC) for the treatment of Transfusion-Dependent Beta Thalassemia (TDT).